Radiopharmaceutical Cdmo Cmo Services Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The radiopharmaceutical CDMO/CMO services market encompasses contract development and manufacturing organizations that support the production of radioactive diagnostic and therapeutic drugs, including PET and SPECT imaging agents and emerging radioligand therapies. Market size estimates for 2025-2026 range from approximately $2.9 billion to $3.75 billion, reflecting variance in research scopes, with a consensus 2026 figure around $3.276 billion. Long-term forecasts diverge, projecting between $5.82 billion and $7.55 billion by 2031-2034, contingent on therapeutic pipeline success and regulatory approvals for new radiopharmaceutical products.

• •Market valued at approximately $3.276 billion in 2026, up from roughly $2.9 billion in 2024
• •Projected CAGR of approximately 9.2% across most forecast models through 2031-2034
• •Forecast 2031-2034 range spans $5.82 billion to $7.55 billion depending on research scope and methodology

The most powerful growth catalyst is the expanding clinical and commercial pipeline of radioligand therapies, particularly Lu-177 and Ac-225-based treatments for prostate cancer and neuroendocrine tumors, which demand complex, multi-step radiochemistry and specialized manufacturing capabilities that many pharma companies cannot develop in-house. Rising pharmaceutical outsourcing more broadly is another structural driver, as drug developers seek to offload the capital-intensive, highly regulated radiopharmaceutical manufacturing process to experienced contract partners. Additional tailwinds include aging patient populations driving greater demand for precision oncology diagnostics, and expanding reimbursement frameworks in major markets that improve commercial viability for radiopharmaceutical products.

• •Rapid clinical expansion of radioligand therapies and theranostics driving demand for complex radiochemistry manufacturing capacity
• •Pharmaceutical outsourcing trend accelerating as developers avoid capital investment in specialized radioactive infrastructure
• •Aging populations and expanded reimbursement supporting broader adoption of radiopharmaceutical diagnostics and therapies

The market is commonly segmented by radioisotope type, including PET isotopes such as Fluorine-18 and Gallium-68, SPECT isotopes such as Technetium-99m and Iodine-131, and therapeutic isotopes including Lutetium-177, Actinium-225, and Copper-67. Service categories typically span clinical and commercial manufacturing, analytical development, stability and release testing, regulatory and pharmacovigilance support, and late-stage process scale-up. Geographically, North America holds the largest share, supported by a dense concentration of cyclotrons, major nuclear medicine departments, and a robust regulatory pathway through the FDA. Europe follows as the second-largest regional market, led by demand from established nuclear medicine networks in Western Europe, while the Asia-Pacific region is growing fastest, driven by expanding healthcare infrastructure and increasing investment in radiopharmaceutical R&D across Japan, South Korea, and Australia.

• •Key segments include PET isotopes (F-18, Ga-68), SPECT isotopes (Tc-99m, I-131), and therapeutic isotopes (Lu-177, Ac-225)
• •North America leads in market share, with Europe second and Asia-Pacific showing the fastest growth rate
• •Service lines span clinical/commercial manufacturing, analytical development, stability testing, and regulatory support

Who are the notable companies in the industry?

Here's a rewritten Competitive Landscape section (~190 words): The competitive landscape is moderately fragmented, combining large, vertically integrated nuclear medicine and radiopharmaceutical companies with smaller, specialized niche providers. These services are integral in optimizing manufacturing processes and providing regulatory guidance, enabling pharmaceutical companies to focus on core drug development objectives, which has encouraged the integration of CRO and CMO capabilities into a unified CDMO model. Among the major companies operating in this market, Cardinal Health is broadening beyond its established radiopharmacy distribution role and shifting from commodity sales toward long-term actinium-225 partnerships, reflecting how isotope production is becoming a strategic growth axis. Curium operates as an integrated nuclear medicine producer with manufacturing depth across diagnostic and therapeutic isotopes. ITM is positioned as a specialized producer focused on high-purity medical radioisotopes and targeted radiopharmaceutical manufacturing. Jubilant Radiopharma brings a vertically integrated radiopharmaceutical manufacturing and distribution network, while SpectronRx contributes specialized contract manufacturing and radiopharmaceutical production capabilities. Together, these players illustrate the mix of integrated producers and specialty CDMOs serving both commercial and clinical-stage demand.

• •Moderate fragmentation with a tier of large vertically integrated players alongside smaller specialty CDMO providers
• •Integrated producers operate cyclotrons, radiopharmacies, and manufacturing in linked networks; specialty CDMOs focus on process development, custom synthesis, or specific isotope chains
• •Manufacturing capacity is geographically concentrated in North America and Western Europe, with emerging hubs in Asia-Pacific

What are the recent trends and outlook?

The long-term outlook points toward sustained double-digit growth, underpinned by the anticipated approval and commercialization of multiple next-generation radiopharmaceuticals targeting cancers with high unmet need, including PSMA-targeted and FAP-targeted radioligand therapies. Near-term constraints include global supply chain vulnerabilities for key radioisotope feedstocks, particularly the aging Mo-99/Tc-99m production infrastructure and limited Ac-225 supply capacity, which may temper growth until new production and supply routes are commissioned. Investment in domestic and regional radiopharmaceutical manufacturing capacity, particularly in Europe and North America, is accelerating as governments prioritize supply chain resilience and on-shoring of critical nuclear medicine infrastructure.

• •Multi-year pipeline of PSMA-targeted and next-generation radioligand therapies expected to drive demand through the 2030s
• •Supply chain constraints for key isotopes, particularly Ac-225 and legacy Mo-99/Tc-99m feedstock, may create near-term capacity bottlenecks
• •Government-backed investment in domestic radiopharmaceutical manufacturing capacity is rising, particularly in North America and Europe